– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results